Information de reference pour ce titreAccession Number: | 00004686-200205100-00013.
|
Author: | Petersen, Kitt Falk 1; Oral, Elif Arioglu 2; Dufour, Sylvie 3; Befroy, Douglas 3; Ariyan, Charlotte 4; Yu, Chunli 1; Cline, Gary W. 1; DePaoli, Alex M. 5; Taylor, Simeon I. 2; Gorden, Phillip 2; Shulman, Gerald I. 1,3,6
|
Institution: | (1)Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA (2)National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA (3)The Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA (4)Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, USA (5)Amgen Inc., Thousand Oaks, California, USA (6)Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, Connecticut, USA
|
Title: | |
Source: | Journal of Clinical Investigation. 109(10):1345-1350, May 2002.
|
Abstract: | Lipodystrophy is a rare disorder that is characterized by selective loss of subcutaneous and visceral fat and is associated with hypertriglyceridemia, hepatomegaly, and disordered glucose metabolism. It has recently been shown that chronic leptin treatment ameliorates these abnormalities. Here we show that chronic leptin treatment improves insulin-stimulated hepatic and peripheral glucose metabolism in severely insulin-resistant lipodystrophic patients. This improvement in insulin action was associated with a marked reduction in hepatic and muscle triglyceride content. These data suggest that leptin may represent an important new therapy to reverse the severe hepatic and muscle insulin resistance and associated hepatic steatosis in patients with lipodystrophy.
Copyright (C) 2002 The American Society for Clinical Investigation, Inc.
|
References: | 1. Rossini, A.A., et al. 1977. Metabolic and endocrine studies in a case of lipoatrophic diabetes. Metabolism. 26:637-650.
2. Reitman, M.L., Arioglu, E., Gavrilova, O., and Taylor, S.I. 2000. Lipoatrophy revisited. Trends Endocrinol. Metab. 11:410-416.
3. Arioglu, E., et al. 2000. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann. Intern. Med. 133:263-274.
4. Shimomura, I., Hammer, R.E., Ikemoto, S., Brown, M.S., and Goldstein, J.L. 1999. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 401:73-76.
5. Oral, E.A, et al. 2002. Efficacy and safety of leptin replacement in lipodystrophy. N. Engl. J. Med. 346:570-578.
6. Maggs, D.G., et al. 1998. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 128:176-185.
7. Szczepaniak, L.S., et al. 1999. Measurement of intracellular triglyceride stores by 1H spectroscopy: validation in vivo. Am. J. Physiol. 276:E977-E989.
8. Blamire, A.M., Graham, G.D., Rothman, D.L., and Prichard, J.W. 1994. Proton spectroscopy of human stroke: assessment of transverse relaxation times and partial volume effects in single volume steam MRS. Magn. Reson. Imaging. 12:1227-1235.
9. Mayerson, A., et al. 2002. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 51:797-802.
10. Lebon, V., et al. 2001. Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle assessed by 31P/13C NMR spectroscopy. J. Clin. Invest. 108:733-737. doi:10.1172/JCI200111775.
11. Lusk, G. 1924. Animal calorimetry: analysis of the oxidation of mixtures of carbohydrates and fat: a correction. J. Biol. Chem. 59:41-42.
12. Petersen, K.F., et al. 2000. Mechanism of troglitazone action in type 2 diabetes. Diabetes. 49:827-831.
13. Miles, J., Glasscock, R., Aikens, J., Gerich, J., and Haymond, M. 1983. A microfluorometric method for the determination of free fatty acids in plasma. J. Lipid Res. 24:96-99.
14. Wolfe, R.R. 1992. Radioactive and stable isotope tracers in biomedicine: principles and practice of kinetic analysis. Wiley-Liss Inc. New York, New York, USA. 49-118.
15. Bligh, E.G., and Dryer, W.J. 1959. A rapid method of total lipid extraction and purification. Canadian J. Biochem. 37:911-917.
16. Klein, S., Jahoor, F., Wolfe, R.R., and Stuart, C.A. 1992. Generalized lipodystrophy: in vivo evidence for hypermetabolism and insulin-resistant lipid, glucose, and amino acid kinetics. Metabolism. 41:893-896.
17. Dresner, A., et al. 1999. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103:253-259.
18. Griffin, M.E., et al. 1999. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes. 48:1270-1274.
19. Kim, J.K., Gavrilova, O., Chen, Y., Reitman, M.L., and Shulman, G.I. 2000. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J. Biol. Chem. 275:8456-8460.
20. Kim, J.K., et al. 2001. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad Sci. USA. 98:7522-7527.
21. Perseghin, G., et al. 1999. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes. 48:1600-1606.
22. Ryysy, L., et al. 2000. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes. 49:749-758.
23. Shulman, G.I. 2000. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106:171-176.
24. Randle, P.J., Garland, P.B., Hales, C.N., and Newsholme, E.A. 1963. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1:785-789.
25. Chen, X., Iqbal, N., and Boden, G. 1999. The effect of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J. Clin. Invest. 103:365-372.
26. Roden, M., et al. 2000. Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in man. Diabetes. 49:701-707.
27. Farooqi, et al. 1999. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 341:879-884.
28. Unger, R.H., Zhou, Y.T., and Orci, L. 1999. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc. Natl. Acad. Sci. USA. 96:2327-2332.
|
Language: | English.
|
Document Type: | Articles.
|
Journal Subset: | Clinical Medicine. Life Sciences.
|
ISSN: | 0021-9738
|
NLM Journal Code: | hs7, 7802877
|
Annotation(s) | |
|
|